Congress: Keep the nation's drug safety system intact
from The Hill
Using the same backlash politics as some presidential candidates, generic drug lobbyists are pointing to the despised former CEO of Turing Pharmaceuticals, Martin Shkreli, as the reason Congress should weaken drug safety protections, called Risk Evaluation and Mitigation Strategies, which have allowed Americans with cancer, multiple sclerosis and other serious diseases to be treated effectively with medicines that would otherwise not be on the market today.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063